The enormous potential of si RNA as a therapeutic has led to an explosion of interest from the scientific community. There has been intense interest from Big Pharma to capitalise on this new technology but the fact remains that delivery is a key determinant in realizing the full clinical potential of RNA interference. There is an urgent need for better delivery methods to take this technology forward. This book addresses the role of different RNAi molecules in cellular processes as rational for diagnostic and therapeutic approaches. This book will cover RNAi therapeutic design to optimize si RNA potency and reduce off-target effects and current delivery technologies to overcome both intracellular and extracellular barriers. The reader will gain an insight into RNA interference from the cellular mechanisms to screening to si RNA design right through to diagnostic and therapeutic applications.
Spis treści
RNA Interference Pathways and Therapeutic Exploitation RNA Interference.- Synthetic Dicer-Substrate si RNAs as Triggers of RNA Interference.- The Role of Micro RNAs in Natural Tissue Development and Application in Regenerative Medicine.- Intracellular Delivery Considerations for RNAi Therapeutics.- Mucosal Delivery of RNAi Therapeutics.- Nanomedicines for Systemic Delivery of RNAi Therapeutics.- Lipidoids: A Combinatorial Approach to si RNA Delivery.- Polymeric Micelles for si RNA Delivery.- RNAi Therapeutic Delivery by Exosomes.- Aptamer-Mediated si RNA Targeting.- RNAi as Anti-Viral Therapy: The HIV-1 Case.- Genome-Wide RNAi Screen for Identification of Human Host Factors Crucial for Influenza Virus Replication.- The Application of micro RNAs in Cancer Diagnostics.- Therapeutic Application of mi RNAs in Cancer.- Clinical Development of an Inhalable Anti-RSV si RNA Treatment.
O autorze
Kenneth Alan Howard is an Associate Professor and Group Leader at the Department of Molecular Biology at the Interdisciplinary Nanoscience Center (i NANO), Aarhus University, Denmark. His team is based in a highly interdisciplinary setting with research and teaching activities focused on advanced drug delivery, nanomedicine, RNA interference, and inflammation. Dr Howard is CEO of an Aarhus University spin-out company that provides delivery solutions for RNA interference-based therapeutics. Kenneth Alan Howard received a Ph D in Pharmaceutical Science from the University of Nottingham, UK in 1995, and has held postdoctoral positions at the CRC Institute for Cancer Studies, University of Birmingham, UK and the School of Pharmacy, University of London. Dr Howard is an active member of the Controlled Release Society serving on the Board of Scientific Advisors (chair), Nominations Committee and organizer of a CRS Educational workshop “RNA Interference Biology and Therapeutics”.
Więcej książek elektronicznych tego samego autora (ów) / Redaktor
10 884 Ebooki w tej kategorii
